Thyroid-Associated Ophthalmopathy Subtypes and Orbital Antibodies

Not Applicable

Completed

• Conditions: Graves' Ophthalmopathy

• Registration Number: NCT00430547
• Lead Sponsor: Barwon Health

Brief Summary

The purpose of this study is to determine whether radioactive iodine, as compared to anti-thyroid medications, is a risk factor for the development or progression of thyroid-associated ophthalmopathy in patients with hyperthyroidism due to Graves' disease. The other aim of this study is to determine the incidence of the various ophthalmopathy subtypes and the utility of orbital antibodies in the diagnosis, classification and monitoring of patients with thyroid-associated ophthalmopathy.

Detailed Description

Not available

Study Timeline

• Status Verified: 2003-08
• Study Start: 2003-08
• Study Completion: 2006-01
• Study First Submitted: 2007-02-01
• Study First Submitted QC: 2007-02-01
• Last Update Submitted: 2007-02-01
• Study First Posted: 2007-02-02
• Last Update Posted: 2007-02-02

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 60

Inclusion Criteria

• Graves' disease diagnosed in the last 3 months, regardless of the presence of ophthalmopathy

Exclusion Criteria

• Pre-existing eye disease: e.g. orbital surgery, orbital irradiation or significant loss of vision
• Age < 18 years
• Inability to consent to participation in the study
• Pregnancy
• History of radio-active iodine therapy

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Primary Outcome Measures

Name	Time	Method
Onset or progression of ophthalmopathy following radio-active iodine therapy

Trial Locations

Locations (1)

Barwon Health - The Geelong Hospital; 🇦🇺 Geelong, Victoria, Australia